[go: up one dir, main page]

WO2008030964A3 - Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits - Google Patents

Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits Download PDF

Info

Publication number
WO2008030964A3
WO2008030964A3 PCT/US2007/077763 US2007077763W WO2008030964A3 WO 2008030964 A3 WO2008030964 A3 WO 2008030964A3 US 2007077763 W US2007077763 W US 2007077763W WO 2008030964 A3 WO2008030964 A3 WO 2008030964A3
Authority
WO
WIPO (PCT)
Prior art keywords
zeolites
noncalcium
products
calcium salt
added calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/077763
Other languages
English (en)
Other versions
WO2008030964A2 (fr
Inventor
Robert L Bedard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Honeywell UOP LLC
Original Assignee
UOP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UOP LLC filed Critical UOP LLC
Priority to CN200780033033A priority Critical patent/CN101677848A/zh
Priority to EP07841971A priority patent/EP2059187A2/fr
Publication of WO2008030964A2 publication Critical patent/WO2008030964A2/fr
Publication of WO2008030964A3 publication Critical patent/WO2008030964A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des zéolites à échange de calcium qui sont efficaces dans une hémostase. La raison pour laquelle des zéolites à échange de Ca sont nécessaires n'a pas été expliquée dans la technique antérieure, excepté que la présence d'ions Ca2+ est importante dans le mécanisme de coagulation. On sait maintenant que l'ajout d'ions Ca2+ ralentit réellement la coagulation du sang. L'utilisation de zéolites de Ca apparaît comme étant efficace dans une hémostase simplement du fait qu'elles ne suppriment pas le Ca2+ critique du sang par un échange d'ions. Une zéolite de NaA pourvue d'une quantité efficace de sel de Ca2+ ajouté est presque aussi active dans une coagulation que la forme à échange de Ca de zéolite de CaA.
PCT/US2007/077763 2006-09-08 2007-09-06 Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits Ceased WO2008030964A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN200780033033A CN101677848A (zh) 2006-09-08 2007-09-06 具有加入的钙盐的非钙沸石在止血装置和产品中的用途
EP07841971A EP2059187A2 (fr) 2006-09-08 2007-09-06 Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53036906A 2006-09-08 2006-09-08
US11/530,369 2006-09-08

Publications (2)

Publication Number Publication Date
WO2008030964A2 WO2008030964A2 (fr) 2008-03-13
WO2008030964A3 true WO2008030964A3 (fr) 2008-05-08

Family

ID=39158050

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/077763 Ceased WO2008030964A2 (fr) 2006-09-08 2007-09-06 Utilisation de zéolites non-calciques avec sel de calcium ajouté dans des dispositifs hémostatiques, et produits

Country Status (3)

Country Link
EP (1) EP2059187A2 (fr)
CN (1) CN101677848A (fr)
WO (1) WO2008030964A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2414225C1 (ru) * 2009-12-10 2011-03-20 Валерий Владимирович Бояринцев Местное гемостатическое средство

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008202A (en) * 1988-11-29 1991-04-16 Sequoia Turner Corporation Blood diluent for red blood cell analysis
US5861146A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Method for reducing body odor
US5863581A (en) * 1996-04-25 1999-01-26 Lipton, Division Of Conopco, Inc. Tea processing with zeolites
US6100414A (en) * 1998-04-02 2000-08-08 Eastman Chemical Company Cyclopentadienyl transition metal compounds useful as polymerization catalysts
US6521265B1 (en) * 2000-02-09 2003-02-18 Biolife, L.L.C. Method for applying a blood clotting agent
US20030133990A1 (en) * 2000-10-13 2003-07-17 Hursey Francis X. Bandage using molecular sieves
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
US20040258826A1 (en) * 2001-12-20 2004-12-23 Navarro Y Koren Peter Antonio Matrix-forming composition containing pectin
US20050074505A1 (en) * 2003-09-12 2005-04-07 Hursey Francis X. Calcium zeolite hemostatic agent
US20060178609A1 (en) * 2005-02-09 2006-08-10 Z-Medica, Llc Devices and methods for the delivery of molecular sieve materials for the formation of blood clots

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008202A (en) * 1988-11-29 1991-04-16 Sequoia Turner Corporation Blood diluent for red blood cell analysis
US5863581A (en) * 1996-04-25 1999-01-26 Lipton, Division Of Conopco, Inc. Tea processing with zeolites
US5861146A (en) * 1997-06-09 1999-01-19 The Procter & Gamble Company Method for reducing body odor
US6100414A (en) * 1998-04-02 2000-08-08 Eastman Chemical Company Cyclopentadienyl transition metal compounds useful as polymerization catalysts
US6521265B1 (en) * 2000-02-09 2003-02-18 Biolife, L.L.C. Method for applying a blood clotting agent
US20030133990A1 (en) * 2000-10-13 2003-07-17 Hursey Francis X. Bandage using molecular sieves
US20040219208A1 (en) * 2001-08-03 2004-11-04 Ryu Kawamura Sustained-release medicines
US20040258826A1 (en) * 2001-12-20 2004-12-23 Navarro Y Koren Peter Antonio Matrix-forming composition containing pectin
US20050074505A1 (en) * 2003-09-12 2005-04-07 Hursey Francis X. Calcium zeolite hemostatic agent
US20060178609A1 (en) * 2005-02-09 2006-08-10 Z-Medica, Llc Devices and methods for the delivery of molecular sieve materials for the formation of blood clots

Also Published As

Publication number Publication date
EP2059187A2 (fr) 2009-05-20
CN101677848A (zh) 2010-03-24
WO2008030964A2 (fr) 2008-03-13

Similar Documents

Publication Publication Date Title
NZ574653A (en) Solid dressing for treating wounded tissue
PH12013500578A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
WO2007141278A3 (fr) molécules de liaison humaines à activité bactéricide contre les entérococci et leurs emplois
WO2007141274A3 (fr) Molécules de liaison humaines présentant une activité bactéricide contre les staphylocoques et leurs utilisations
WO2012122044A3 (fr) Dispositif hémostatique à base de collagène fluide et procédés d'utilisation
IL186907A0 (en) 4-(pyridin-3-yl)-2-(pyridin-2-yl)-1,2-dihydro-3h-pyrazol-3-one derivatives as specific hifprolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases
WO2008131154A3 (fr) Compositions de fibrine contenant des composés de strontium
BR112012030037A2 (pt) composição terapêutica oral
WO2008127287A3 (fr) Matériaux et méthodes de traitement de plaies
WO2008127497A3 (fr) Compositions hémostatiques et procédés d'utilisation
WO2007093539A3 (fr) Alanines substituées par benzoyle
EP1865967A4 (fr) Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
GB2462228A (en) Providing hemostasis in anticoagulated blood by using zeolites
PH12016500828A1 (en) (aza) pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis
WO2007120374A3 (fr) Composes anti-arenaviridae
EP2922535A1 (fr) Inhibiteurs de thrombine
EP2653166A3 (fr) Composition pharmaceutique pour le traitement des plaies et procédés associés
WO2007015107A3 (fr) Agent therapeutique
WO2005086895A3 (fr) Modulateurs de la fonction canal ionique
HRP20230336T1 (hr) Sastavi protiv krvarenja
WO2007138328A3 (fr) NOUVELLES APPLICATIONS DE LA PROTÉINE Sbi DE STAPHYLOCOCCUS AUREUS
WO2012061248A8 (fr) Nouveaux inhibiteurs spécifiques de la protéase ns3 du vhc
WO2009000551A8 (fr) Utilisation d'une composition synergétique en tant qu'agent thérapeutique ou agent de désinfection
BRPI0607031A2 (pt) combinação sinergìstica de compostos ativos fungicidas
WO2008157593A3 (fr) Agents hémostatiques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780033033.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07841971

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007841971

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2228/DELNP/2009

Country of ref document: IN